SYRE•benzinga•
Leerink Partners Initiates Coverage On Spyre Therapeutics with Outperform Rating, Announces Price Target of $45
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 8, 2025 by benzinga